Showing posts with label Professional Compounding Centers of America. Show all posts
Showing posts with label Professional Compounding Centers of America. Show all posts

Sunday, February 9, 2014

Professional Compounding Centers of America, Inc and JRX Biotechnology, Inc have sued Freedom Pharmaceuticals

JRX Biotechnology, Inc. et al v. Freedom Pharmaceuticals, Inc.

Plaintiff:Professional Compounding Centers of America, Inc. and JRX Biotechnology, Inc.
Defendant:Freedom Pharmaceuticals, Inc.
 
Case Number:8:2014cv00079
Filed:January 17, 2014
 
Court:California Central District Court
Referring Judge:Robert N. Block
Presiding Judge:James V. Selna
 
Nature of Suit:Patent

Saturday, September 7, 2013

Professional Compounding Centers of America, Inc. (PCCA)'s shares of Imprimis Pharmaceuticals, Inc: Initial SEC Filings

because copy of actual page does not fit nicely on page, link is also provided  here


Filing Detail
Form 3 - Initial statement of beneficial ownership of securities
SEC Accession No. 0001078782-13-000418
Filing Date
2013-03-08
Accepted
2013-03-08 19:39:15
Documents
1
Period of Report
2012-08-31
Filing Date Changed
2013-03-08
Document Format Files
SeqDescriptionDocumentTypeSize
1PRIMARY DOCUMENTprimary_doc.html3 
1PRIMARY DOCUMENTprimary_doc.xml32068
 Complete submission text file0001078782-13-000418.txt 3850
Mailing Address437 S. HWY 101STE 209SOLANA BEACH CA 92075
Business Address437 S. HWY 101STE 209SOLANA BEACH CA 92075858-433-2800
Imprimis Pharmaceuticals, Inc. (Issuer) CIK: 0001360214 (see all company filings)
IRS No.: 450567010 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
Assistant Director 1
Mailing Address9901 S. WILCREST DR.HOUSTON TX 77099
Business Address9901 S. WILCREST DR.HOUSTON TX 77099281-933-6948
Professional Compounding Centers of America, Inc. (Reporting) CIK: 0001558044 (see all company filings)
State of Incorp.: TX | Fiscal Year End: 1231
Type: 3 | Act: 34 | File No.: 001-35814 | Film No.: 13678993

Monday, March 18, 2013

New Drug Compounding Voice Emerges In Opposition To Federal Action


FDA Week - 03/15/2013


A private company that supplies equipment and chemicals to compounding pharmacies is vociferously opposing any federal action -- from Congress or FDA -- on drug compounding, asserting that state boards of pharmacy have clear authority as the sole regulators with jurisdiction over the practice. The company, Professional Compounding Centers of America, has clients that are also part of compounders' main lobby group, the International Academy of Compounding Pharmacists, although the company diverges from IACP on key points in asserting that federal legislation is not necessary and FDA had no role in overseeing events that led to a nationwide meningitis outbreak.964 words

Subscription required here

Friday, September 7, 2012

Strategic Agreement Launches Novel Drug Development Model


Professional Compounding Centers of America (PCCA) Invests $4 Million In San Diego-based Imprimis Pharmaceuticals; Agrees to Share Topical Drug-Delivery Knowledge and Technology to Bring New Medicines to Market
SOLANA BEACH, Calif., Sept. 7, 2012 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (IMMY: OTCQB) today announced a strategic development and investment agreement with Houston-based Professional Compounding Centers of America, Inc. (PCCA). The agreement will allow the companies to develop and share drug-formulation technology, with the goal of creating a new generation of treatments for muscle and joint pain, neuropathic pain and other conditions. PCCA also made a $4 million equity investment in Imprimis in a private transaction.
The agreement will give Imprimis exclusive non-PCCA-member access to PCCA's topical technologies and formulation know-how for delivering drugs directly through the skin. The arrangement is intended to identify development opportunities for new topical medications for new therapeutic applications.
Imprimis' lead drug candidate, Impracor™, a topical non-steroidal anti-inflammatory cream, is expected to enter Phase 3 clinical trials early in 2013. When approved for sale, Impracor would be applied to the site of muscle or joint pain, delivering a clinical dose of medication to the affected area without potential side effects such as stomach irritation or liver problems that have been associated with ingestible, non-steroidal, anti-inflammatory drugs.
The company has also developed Accudel™, a patented topical-delivery platform that can serve as a delivery vehicle for other medications.

To read the remainder of the article, click here.